tigecycline · Fresenius Kabi Usa · NDA 205645, 208744, 211158
Tigecycline
Earliest generic entry, as listed
Open now
No marketed reference-listed strength; date taken from all listed strengths.
No unexpired patents or exclusivities are listed for this product.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 9855335 | product | 7 Apr 2033 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 205645 · 001 · RLD · discontinued | powder, intravenous | 50MG/VIAL | open |
| 208744 · 001 · discontinued | powder, intravenous | 50MG/VIAL | open |
| 211158 · 001 | powder, intravenous | 50MG/VIAL | 7 Apr 2033 |